Marked occipital hypometabolism on FDG-PET in patients with idiopathic RBD may predict Parkinson’s disease
Objective: In the present study, we tried to elucidate if the occipital hypometabolism detected by [(18) F]-fluoro-d-glucose (FDG) positron emission tomography (PET) scan in patients with idiopathic…Protein levels of SV2A and VGLUT1 in brain tissue from patients with Parkinson’s disease, dementia with Lewy bodies and Alzheimer’s disease
Objective: The objective of this study was to investigate whether SV2A and/or VGLUT1 are suitable as markers for synaptic degeneration in neurodegenerative disorders and could…Novel PET Tracers of alpha-synuclein for the diagnosis of Parkinson’s disease
Objective: The aim of our project is to develop small molecular weight compounds (Morphomers™) which bind selectively to alpha-synuclein (aSyn) aggregates, in order to generate…Targeted over-expression with AAV-mediated human α-synuclein in a rat model of Parkinson’s disease – Validation of novel fine motor functional effects
Objective: Targeted over-expression of human α-synuclein using viral-vector mediated gene delivery into the substantia nigra of rats and non-human primates has been reported to lead…Correlation between neuro-behavioral symptoms, cognition and gait in patients with dementia with Lewy bodies (DLB)
Objective: To determine the prevalence of neurobehavioral disturbances and their relationship to gait and cognitive impairment in DLB. Background: The recent literature has conceptualized that…The clinical characteristics of Lewy body disease showed autonomic failures preceding motor signs
Objective: There are few cases of Lewy body disease who have been initially diagnosed as pure autonomic failure(PAF), because they had only autonomic symptoms for…Utility of the Mayo sleep questionnaire in predicting final autopsy diagnosis of alpha-synucleinopathy
Objective: To ascertain the utility of the MSQ in predicting final autopsy diagnosis of an alpha-synuleinopathy. Background: Idiopathic REM sleep behavior disorder (iRBD) is a…Safety of nelotanserin in a randomized placebo-controlled phase 2 study
Objective: To explore the safety of nelotanserin in a phase 2 study in patients with nelotanserin. Background: Nelotanserin is a highly selective and poent inverse…Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia
Objective: To understand the effects of nelotanserin on objective sleep parameters in a phase 2 study in patients with primary insomnia. Background: Nelotanserin is a…Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia
Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »